Inhibitory effect of the selective serotonin 5-HT3 receptor antagonist RAMOSETRON (cas 132036-88-5) on duodenal acidification-induced gastric hypersensitivity in rats
-
Add time:08/05/2019 Source:sciencedirect.com
Irritable bowel syndrome (IBS) and functional dyspepsia (FD) are both functional gastrointestinal disorders and frequently co-occur in patients. While one cause of FD appears to be gastric hypersensitivity, whether the hypersensitivity is affected by IBS treatments remains unclear, given the lack of appropriate animal models for testing. Here, we established an experimental model of duodenal acidification-induced gastric hypersensitivity in conscious rats. The model involved duodenal acidification induced by the infusion of hydrochloric acid into the proximal duodenum, with the nociceptive response being determined as the change in mean arterial pressure (MAP) during gastric distension via an indwelling latex balloon. Using our model we evaluated the effects of duodenal acidification, increased distension pressure, and orally administered therapeutic agents for IBS with diarrhea (IBS-D). Duodenal acidification enhanced the pressor response during gastric distension, and pretreatment with the opioid κ-receptor agonist fedotozine (10 mg/kg, intra-arterial) inhibited the pressor response. Pressure levels of 15–60 mmHg increased MAP in response to gastric distension. The serotonin 5-HT3 receptor antagonist RAMOSETRON (cas 132036-88-5) (30 μg/kg) inhibited MAP increase induced by duodenal acidification, with no other IBS-D therapeutic agents showing any effect. In contrast, the serotonin 5-HT3 receptor agonist m-chlorophenylbiguanide (1 mg/kg) significantly enhanced the pressor response during gastric distension. These findings indicate that the serotonin 5-HT3 receptor plays a key role in duodenal acidification-induced gastric hypersensitivity in rats, suggesting that ramosetron may reduce FD symptoms by ameliorating sensitized gastric perception.
We also recommend Trading Suppliers and Manufacturers of RAMOSETRON (cas 132036-88-5). Pls Click Website Link as below: cas 132036-88-5 suppliers
Prev:Effect of RAMOSETRON (cas 132036-88-5) on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats
Next:Electrical and humidity-sensing properties of 1-(4-carboxylic acid phenyl)-2,5-dimethyl-1H-pyrrole doped with both KOH and K2CO3 salts) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Effect of RAMOSETRON (cas 132036-88-5) on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats08/04/2019
- Comparison of RAMOSETRON (cas 132036-88-5) with ondansetron for prevention of postoperative nausea and vomiting in patients undergoing gynaecological surgery08/03/2019
- Comparison of RAMOSETRON (cas 132036-88-5), dexamethasone, and a combination of RAMOSETRON (cas 132036-88-5) and dexamethasone for the prevention of postoperative nausea and vomiting in Korean women undergoing thyroidectomy: A double-blind, randomized, controlled study08/02/2019
- Intravenous, Oral, and the Combination of Intravenous and Oral RAMOSETRON (cas 132036-88-5) for the Prevention of Nausea and Vomiting After Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Controlled Trial08/01/2019
- RAMOSETRON (cas 132036-88-5) Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women07/31/2019
- RAMOSETRON (cas 132036-88-5) vs. RAMOSETRON (cas 132036-88-5) plus dexamethasone for the prevention of postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy: Prospective, randomized, and double-blind study07/30/2019
- Effect of RAMOSETRON (cas 132036-88-5) on Stool Consistency in Male Patients With Irritable Bowel Syndrome With Diarrhea07/29/2019
- Effects of prophylactic RAMOSETRON (cas 132036-88-5) and ondansetron on corrected QT interval during general anesthesia07/28/2019
- Comparison of RAMOSETRON (cas 132036-88-5) With Ondansetron for Prevention of Intrathecal Morphine-Induced Nausea and Vomiting After Primary Total Knee Arthroplasty: A Randomized Control Trial07/27/2019


